NIKKEI 225
38,587.87 -45.15 (-0.12%) HANG SENG
18,072.41 -262.91 (-1.43%) CRUDE OIL
82.34 +0.17 (+0.21%) GOLD FUTURES
2,378.10 +9.10 (+0.38%) DOW
39,134.76 +299.90 (+0.77%) Bitcoin GBP
51,007.90 -668.63 (-1.29%)
PTCT Sep 2024 27.000 call
- PR Newswire
Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington's Disease Patients
PTC Therapeutics, Inc. (NASDAQ: PTCT) today shared interim results from the Phase 2 PIVOT-HD study of PTC518 in Huntington's disease (HD) patients. At Month 12, PTC518 treatment resulted in dose-dependent lowering of mutant huntingtin (mHTT) protein in the blood and cerebrospinal fluid (CSF) in the interim cohort of patients. In addition, favorable trends were demonstrated on several relevant HD clinical assessments including Total Motor Score (TMS) and Composite Unified Huntington's Disease Rat
- PR Newswire
PTC Therapeutics to Participate at Upcoming Investor Conference
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conference:
- PR Newswire
PTC Therapeutics Announces Validation of Sepiapterin European MAA
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the sepiapterin MAA for PKU has been validated and accepted for review by the EMA.
